ࡱ> GIFc &bjbj >BMbMb9  8D*,!Vl]]]O!Q!Q!Q!Q!Q!Q!$#&u!]]]]]u!!0yyy]|O!y]O!yy: , pT|~\Z ;!!<! .L'3FL' L' L]]y]]]]]u!u!y]]]!]]]]L']]]]]]]]] B `: IRB STUDY #XXXXXXXXXX WEBER STATE UNIVERSITY INFORMED CONSENT [Insert Title of Study] You are invited to participate in a research study of [Insert general statement about study]. You were selected as a possible subject because [Explain how the subject was identified]. We ask that you read this form and ask any questions you may have before agreeing to be in the study. The study is being conducted by [Indicate the investigators names and University/Departmental affiliation]. It is funded by [Indicate study sponsor, if any, and state if the sponsor is also the manufacturer of the drug/device being studied, if applicable]. STUDY PURPOSE The purpose of this study is to [Explain why the research is being done using language understandable to the subject, e.g., eighth grade level. Clarify if the study involves the use of an investigational drug or device, including that investigational means it is not approved by the Food and Drug Administration (FDA))]. NUMBER OF PEOPLE TAKING PART IN THE STUDY: If you agree to participate, you will be one of [Insert single number if the study involves only one site or local and national numbers if a multi-center study. It may also be appropriate to clarify the number of subjects in different cohorts or groups, if applicable.] subjects who will be participating in this research. PROCEDURES FOR THE STUDY: If you agree to be in the study, you will do the following things: [Explain in language understandable to the subject, all procedures/tests, including surveys, focus groups, audio or video taping, assignment to study groups, administration of study medications, x-rays, blood draws, study visits, etc., which will be employed in the study. Clarify where the procedures will be performed, how frequently they will be performed, and the expected amount of time each procedure and/or visit will last. Also clarify the total duration of the study. Identify which procedures are experimental and which are standard procedures. If blood is to be drawn, explain how and from where the blood will be drawn, e.g., from a vein in your arm. Indicate the total number of times blood will be drawn, the amount of blood to be drawn each time, and the total amount of blood to be drawn over the course of the study. Translate the amount to be drawn to common measurement terms, such as teaspoonfuls or cupfuls)]. RISKS OF TAKING PART IN THE STUDY: For face-to-face research, the risks include the possibility of being infected by the novel coronavirus 2019 (COVID-19) or other communicable diseases. [Clearly explain in a language understandable to the subjects any risk (side effects, and/or discomforted) involved to the participant(s). Please include a statement that there may be risk that is currently unforeseeable.] Examples of possible risk/side effect statements include: The risks of completing the survey are being uncomfortable answering the questions. The risks of possible loss of confidentiality The risks of drawing blood include, pain, bruising, and rarely, infection.) The side effects associated with taking [Insert study medication] are mild diarrhea, confusion, sleepiness, depression, anxiety, and headaches. In rare instances, hair loss, rash, decrease in the number of red and white blood cells and blood platelets, which could cause fatigue, increase in infection and/or bleeding can occur. BENEFITS OF TAKING PART IN THE STUDY You (will/will not) receive payment for taking part in this study. [Describe the details and any conditions of payment. If subjects will not be paid, this should be stated.] ALTERNATIVES TO TAKING PART IN THE STUDY: Instead of being in the study, you have these options: [List appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subjects. If the only alternative is not participating, this should be stated.] COSTS/ COMPENSATION FOR INJURY [Detail any cost of participating in this investigation] [If a source of funds for payment of treatment costs is NOT available, include the following statement:] In the event of physical injury resulting from your participation in this research, necessary medical treatment will be provided to you and billed as part of your medical expenses. Costs not covered by your health care insurer will be your responsibility. Also, it is your responsibility to determine the extent of your health care coverage. There is no program in place for other monetary compensation for such injuries. However, you are not giving up any legal rights or benefits to which you are otherwise entitled. If you are participating in research which is not conducted at a medical facility, you will be responsible for seeking medical care and for the expenses associated with any care received. CONFIDENTIALITY Efforts will be made to keep your personal information confidential. We cannot guarantee absolute confidentiality. Your personal information may be disclosed if required by law. Your identity will be held in confidence in reports in which the study may be published [Include the following statement, if applicable, and databases in which results may be stored. If tape recordings or videotapes are made, explain who will have access, if they will be used for education purposes, and when they will be destroyed.] Organizations that may inspect and/or copy your research records for quality assurance and data analysis include groups such as the study investigator and his/her research associates, the 91Ƶ Institutional Review Board or its designees, the study sponsor, [Insert sponsor name], and (as allowed by law) state or federal agencies, specifically the Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA) [for FDA-regulated research and research involving positron-emission scanning], the National Cancer Institute (NCI) [for research funded or supported by NCI], the National Institutes of Health (NIH) [for research funded or supported by NIH], etc., who may need to access your medical and/or research records. CONTACTS FOR QUESTIONS OR PROBLEMS For questions about the study, contact the researcher [Insert name of investigator] at [Insert telephone number] or the researchers mentor [Insert name of investigator mentor] at [Insert telephone number] For questions about your rights as a research participant or to discuss problems, complaints or concerns about a research study, or to obtain information, or offer input, contact the Chair of the IRB Committee  HYPERLINK "mailto:IRB@weber.edu" IRB@weber.edu. VOLUNTARY NATURE OF STUDY Taking part in this study is voluntary. You may choose not to take part or may leave the study at any time. Leaving the study will not result in any penalty or loss of benefits to which you are entitled. Your decision whether or not to participate in this study will not affect your current or future relations with [Insert appropriate entity, e.g hospital, University]. [If withdrawal from the study prior to completion could pose risk to the subject, state what those risks might be and how orderly termination will occur.] SUBJECTS CONSENT In consideration of all of the above, I give my consent to participate in this research study. I will be given a copy of this informed consent document to keep for my records. I agree to take part in this study. Subjects Printed Name: Subjects Signature: Date: (must be dated by the subject) Printed Name of Person Obtaining Consent: Signature of Person Obtaining Consent: Date: If the study involves children who will be providing their assent on this consent document, rather than on a separate assent document, use the following signatures: Printed Name of Parent: Signature of Parent: Date:     Version Date (if appropriate)  PAGE 2 -.?@AVXY   | ~  ϜϜϜϧϜp *hB'h.5CJ\aJ h>h.56CJ\]aJ *h.5CJ\aJh$h.CJaJh.5CJ\aJ *h$h.5CJ\aJh$h.5CJ\aJh.CJaJh.CJOJQJ^JaJ h|h.CJOJQJ^JaJh.OJQJ^J'.?@XYZ{ |  C D E _  d^ gd.  d^ gdzVdgdzVdgd. $da$gd. dgd. $da$gd. 1 2 I \ D E ` BZg aKMNOSοοοznhKzhKz5CJaJhKzCJaJ *hKz5CJ\aJ *h5h.5CJ\aJ *h.5CJ\aJh5h.CJaJh.5CJ\aJ *hB'hzV5CJ\aJ *hzV5CJ\aJhzV5CJ\aJhzVCJaJh.CJaJhB'h.CJaJ(_ ` NOst  )}BCDijEF ^`gdzVdgdzV hd^hgd.gd/)Cdgd.Sstx  JS?ABCDhiºvj_T_hzV5CJ\aJh.5CJ\aJ *h\`!5CJ\aJ *hzV5CJ\aJ *h8ZhzV5CJ\aJhzVCJaJh.CJaJ *hzV5CJaJ *hKzhKz5CJaJhKzCJaJhKzh/)C5CJ\aJhh/)CCJ\aJh/)CCJ\aJ!Hhj'hKz5CJ\aJhKz5CJaJE~9:;^vvj[PBP幮hfe.hzV5CJ\aJhfe.hzVCJaJ *hfe.hzV5CJ\aJ *hfe.hzVCJaJ *hzV5CJ\aJ *hzVhzV5CJ\aJhghzV6CJ]aJ *hhzV5CJ\aJhhzVCJaJhzVCJaJ hzV5CJOJQJ\^JaJh.5CJ\aJh.CJaJhzV5CJ\aJ *hfe.h.5CJ\aJF;<[\ !!!! hd^hgdzVdgd.dgdzVhCE @ [ \ a x ߺsg *hgh.CJaJ *hgh.5CJ\aJhfe.h.CJaJ *hfe.h.5CJ\aJh.CJaJhzV5CJ\aJh.5CJ\aJh=hzVCJaJ *hhzV5CJ\aJhLYGhzVCJaJhghzVCJaJhzVCJaJh hzV6CJ]aJ' !!!!!!!!!!!!!!!:#m#r# $ $ $$%%%'%(%)%-%.%/%0%;%Z%[%־ⶫsjsjf[hZ4h.CJaJh.h.>*CJaJhZ4h.5CJ\aJh{"Mh.5>*CJ\aJ! *hfe.h.5OJQJ\^Jh.OJQJ^Jh.5CJ\aJh.CJaJha?h60JCJaJh6h6CJaJjh6CJUaJhgh.CJaJh6CJaJhG5=h.CJaJ#! $ $$ $$$$$$%%0%Z%[%%%%%%\&]&v& $ dgd.$ @<dgd.$ |)dgd. $dgd.  @dgd.[%%%%%%%%%%%%%%&<&\&]&s&t&w&&&&&&&&&&&&&&&&&&&۶۟ەs *hhKzCJaJhKz0JCJaJhZjhZUh.OJQJ^Jh{"Mh.>*CJaJh.5CJ\aJhEh.5CJ\aJh.>*CJaJhZ4h.5CJ\aJh.CJaJh{"Mh.5>*CJ\aJh{"Mh.5CJ\aJ&v&w&&&&&&&&&&&&&&&& !d$0*h]hgd. !d0*h]hgd.  @dgd.$ |)dgd.&&&&&&&&&&&нᲮh.OJQJ^JhZhKzhhKzCJaJ$jhhKz0JCJUaJ* h0JCJaJmHnHu*hhKz0JCJaJ!jhhKz0JCJUaJ <P1h:p./ =!"#$% Dps  2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH @`@ 'NormalCJ_HaJmH sH tH X@X ' Heading 1$$(@&a$5CJOJQJ\^JaJDA`D Default Paragraph FontRiR  Table Normal4 l4a (k (No List HH  Balloon TextCJOJQJ^JaJ44 'Header  !4 @4 'Footer  !rR@"r 'Body Text Indent 2 $ P^`Pa$CJOJQJ^JaJRQ@2R ' Body Text 3  @CJOJQJ^JaJ.)@A. ' Page NumberB' QB eComment ReferenceCJaJ<b< e Comment TextCJaJ@jab@ eComment Subject5\6U`6 g Hyperlink >*B*phPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vc:E3v@P~Ds |w< @B 888; S [%&& _ F!v&&X+24;!8@0(  B S  ?C J UX^i}dTXjw (8s +9opx<@33333333333333333333333s ? A /s*5_ ^`OJQJo( 8^8`OJQJo( ^`OJQJo(o  p^ `OJQJo(  @ ^ `OJQJo( x^x`OJQJo( H^H`OJQJo(o ^`OJQJo( ^`OJQJo(h^`OJQJ^Jo(hpp^p`OJQJ^Jo(oh@ @ ^@ `OJQJ^Jo(h^`OJQJ^Jo(h^`OJQJ^Jo(oh^`OJQJ^Jo(h^`OJQJ^Jo(hPP^P`OJQJ^Jo(oh  ^ `OJQJ^Jo(s*           D_O \`!/)CzVka=9sK6.ZKz@@Unknown Windows UserG.[x Times New Roman5Symbol3. .[x ArialE Californian FB5. .[`)Tahoma?= .Cx Courier New;WingdingsA$BCambria Math"hȋȋS77!4o2q?s '2!xx ,0IUPUI and CLARIAN INFORMED CONSENT STATEMENT FORsaellis Windows User  Oh+'0 (4 T ` l x4IUPUI and CLARIAN INFORMED CONSENT STATEMENT FORsaellis Normal.dotmWindows User2Microsoft Office Word@^в@BG/@8Z~\@8Z~\ ՜.+,D՜.+,` hp  IUPUI7 1IUPUI and CLARIAN INFORMED CONSENT STATEMENT FOR Title 8@ _PID_HLINKSAd2mailto:IRB@weber.edu  !#$%&'()*+,-./012345789:;<=?@ABCDEHRoot Entry F0|~\J1Table"`'WordDocument>BSummaryInformation(6DocumentSummaryInformation8>CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q